Guardant Health

Paid

Precision oncology via high-fidelity liquid biopsy and AI-driven genomic profiling.

Capabilities: Genomic Profiling Minimal Residual Disease (MRD) Monitoring Early Cancer Screening Clinical Trial Matching Therapy Selection

Visit Website

9.5

Protocol Reliability Score

Overview

Guardant Health is a pioneering precision oncology company specializing in liquid biopsy technology to track cancer through blood tests. By 2026, their technical architecture heavily leverages proprietary 'Digital Sequencing' and advanced AI algorithms to distinguish minute signals of circulating tumor DNA (ctDNA) from background genomic noise. Their platform serves as a critical decision-support layer for oncologists, providing comprehensive genomic profiling (CGP) that informs therapy selection, monitors minimal residual disease (MRD), and facilitates early cancer detection. The market position of Guardant Health is defined by its FDA-approved companion diagnostics, such as Guardant360 CDx, which integrates directly with clinical workflows. Their AI stack focuses on methylation analysis and fragmentomics, allowing for high-sensitivity detection of early-stage malignancies. The company operates a cloud-based reporting infrastructure that enables healthcare providers to access longitudinal patient data, compare genomic trends over time, and identify clinical trial matches via automated matching engines.

Advanced Technology

Digital Sequencing Technology

A proprietary method using physical and bioinformatic barcodes to reduce sequencing error rates by 10,000x, enabling detection of variants at 0.1% allele frequency.